Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T cells AIC100

A preparation of autologous T lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) containing the Inserted (I) domain variant of lymphocyte function-associated antigen-1 (LFA-1) which targets intercellular adhesion molecule-1 (ICAM-1 or CD54), and the co-stimulatory signaling domains of CD28, 4-1BB (CD137) and CD3zeta, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-ICAM-1-CAR-CD28-4-1BB-CD3zeta-expressing T cells AIC100 recognize and kill ICAM-1-expressing tumor cells. ICAM-1, normally expressed on leukocytes and endothelial cells, may be overexpressed in a variety of cancers. CAR-T cells AIC100 are also engineered to express somatostatin receptor subtype 2 (SSTR2), allowing the imaging of the CAR-T cells in patients.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous ICAM-1-targeted CAR T cells AIC100
autologous ICAM-1-targeted CAR-T cells AIC100
autologous ICAM-1-targeted CAR-T lymphocytes AIC100
CAR-T cells AIC100
Code name:AIC 100
AIC-100
AIC100
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search